Jinna Dai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jinna Dai has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Chunjian Gu
Department of Orthopedics, First Hospital of China Medical University, Shenyang, China
1 shared publication Fushun Li
National Clinical Research Center for Medical Auxiliary Technology ( Laboratory Medicine), Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang 110001, China
1 shared publication- Hongyang Li
Department of Orthopedics, First Hospital of China Medical University, Shenyang, China
1 shared publication Hua Nian
National Clinical Research Center for Medical Auxiliary Technology ( Laboratory Medicine), Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang 110001, China
1 shared publication- Jing Hang
Department of Obstetrics and Gynecology, Center for Reproductive Medicine, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, China
1 shared publication - Jinpeng Wang
Department of Orthopedics First Hospital of China Medical University Shenyang China
1 shared publication
Latest Publications
- Open Access
A Dual-Phase Strategy to Integrate the VITEK MS RUO Database into Routine Clinical Practice: From Validation of Analytical Performance to Implementation of an Automated Workflow
Background: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is pivotal in clinical microbiology. The VITEK MS Research Use Only (RUO) database offers broader species coverage, yet its clinical adoption is hindered by insufficient performance validation against the approved in vitro diagnostic (IVD) database and inefficient manual operational workflows. Objective: This two-phase study first aimed to develop and evaluate an automated integrated workflow to enhance laboratory efficiency and diagnostic capability. Methods: The RUO database’s two-tier identification architecture was utilized and in-house automated relay software was developed to parse IVD results and fully automate RUO reanalysis. Phase 1 (Mar 2021–Jun 2022) involved parallel manual testing of 2,432 isolates with both databases to analyze concordance and supplementary performance. Phase 2 (Jul–Nov 2022) prospectively incorporated 3,954 isolates to implement and assess the “IVD screening – automated RUO reanalysis” workflow. Results: Phase 1 demonstrated high RUO-IVD concordance (95.7% species/genus agreement). The RUO database correctly identified 98.9% of isolates and provided valid supplementary identification for 84.4% (108/128) of IVD-failed cases, with Tier 2 contributing 28.9%. Phase 2 revealed that the integrated workflow increased the overall identification rate from 95.5% to 98.7%, with Tier 2 contributing an additional 14.5%. The automated software reduced reanalysis turnaround time by > 75%, saving consumables and labor. Conclusion: The VITEK MS RUO database is a reliable and complementary tool to the IVD database. Integration with automated software creates an efficient, compliant clinical workflow, providing a practical model to enhance pathogen identification for infectious disease management. IMPORTANCE: The present study bridges the validation-to-application gap for the VITEK MS RUO database. We confirm its high concordance (95.7%) and complementary value to the IVD database, quantify the impact of manual workflow inefficiency and introduce an automated software solution. The strategy highlights the key role of Reference Spectra (Tier 2) in expanding coverage and simultaneously improves diagnostic efficacy (∼99% ID rate), operational efficiency (> 75% time saved) and cost-effectiveness, offering a practical model to accelerate pathogen reporting and to guide therapy.
Open AccessA Dual-Phase Strategy to Integrate the VITEK MS RUO Database into Routine Clinical Practice: From Validation of Analytical Performance to Implementation of an Automated Workflow
Background: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is pivotal in clinical microbiology. The VITEK MS Research Use Only (RUO) database offers broader species coverage, yet its clinical adoption is hindered by insufficient performance validation against the approved in vitro diagnostic (IVD) database and inefficient manual operational workflows. Objective: This two-phase study first aimed to develop and evaluate an automated integrated workflow to enhance laboratory efficiency and diagnostic capability. Methods: The RUO database’s two-tier identification architecture was utilized and in-house automated relay software was developed to parse IVD results and fully automate RUO reanalysis. Phase 1 (Mar 2021–Jun 2022) involved parallel manual testing of 2,432 isolates with both databases to analyze concordance and supplementary performance. Phase 2 (Jul–Nov 2022) prospectively incorporated 3,954 isolates to implement and assess the “IVD screening – automated RUO reanalysis” workflow. Results: Phase 1 demonstrated high RUO-IVD concordance (95.7% species/genus agreement). The RUO database correctly identified 98.9% of isolates and provided valid supplementary identification for 84.4% (108/128) of IVD-failed cases, with Tier 2 contributing 28.9%. Phase 2 revealed that the integrated workflow increased the overall identification rate from 95.5% to 98.7%, with Tier 2 contributing an additional 14.5%. The automated software reduced reanalysis turnaround time by > 75%, saving consumables and labor. Conclusion: The VITEK MS RUO database is a reliable and complementary tool to the IVD database. Integration with automated software creates an efficient, compliant clinical workflow, providing a practical model to enhance pathogen identification for infectious disease management. IMPORTANCE: The present study bridges the validation-to-application gap for the VITEK MS RUO database. We confirm its high concordance (95.7%) and complementary value to the IVD database, quantify the impact of manual workflow inefficiency and introduce an automated software solution. The strategy highlights the key role of Reference Spectra (Tier 2) in expanding coverage and simultaneously improves diagnostic efficacy (∼99% ID rate), operational efficiency (> 75% time saved) and cost-effectiveness, offering a practical model to accelerate pathogen reporting and to guide therapy.
- Open Access
- 18 February 2025
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 14 (2) , 111-123
Development and validation of a novel prediction model for osteoporosis
Aims: We aimed to develop and validate a novel prediction model for osteoporosis based on serotonin, fat-soluble vitamins, and bone turnover markers to improve prediction accuracy of osteoporosis.Methods: Postmenopausal women aged 55 to 65 years were recruited and divided into three groups based on DXA (normal, osteopenia, and osteoporosis). A total of 109 participants were included in this study and split into healthy (39/109, 35.8%), osteopenia (35/109, 32.1%), and osteoporosis groups (35/109, 32.1%). Serum concentrations of serotonin, fat-soluble vitamins, and bone turnover markers of participants were measured. Stepwise discriminant analysis was performed to identify efficient predictors for osteoporosis. The prediction model was developed based on Bayes and Fisher’s discriminant functions, and validated via leave-one-out cross-validation. Normal and empirical volume under the receiver operating characteristic (ROC) surface (VUS) tests were used to evaluate predictive effects of variables in the prediction model.Results: Significant variables including oestrogen (E2), total procollagen type 1 amino-terminal propeptide (TP1NP), parathyroid hormone (PTH), BMI, vitamin K, serotonin, osteocalcin (OSTEOC), vitamin A, and vitamin D3 were used for the development of the prediction model. The training accuracy for normal, osteopenia, and osteoporosis is 74.4% (29/39), 80.0% (28/35), and 85.7% (30/35), respectively, while the total training accuracy is 79.8% (87/109). The internal validation showed excellent performance with 72.5% testing accuracy (72/109). Among these variables, serotonin and vitamin K exert important roles in the prediction of osteoporosis.Conclusion: We successfully developed and validated a novel prediction model for osteoporosis based on serum concentrations of serotonin, fat-soluble vitamins, and bone turnover markers. In addition, interactive communication between serotonin and fat-soluble vitamins was observed to be critical for bone health in this study.Cite this article: Bone Joint Res 2025;14(2):111–123.
- 18 February 2025
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 14 (2) , 111-123
Open AccessDevelopment and validation of a novel prediction model for osteoporosis
Aims: We aimed to develop and validate a novel prediction model for osteoporosis based on serotonin, fat-soluble vitamins, and bone turnover markers to improve prediction accuracy of osteoporosis.Methods: Postmenopausal women aged 55 to 65 years were recruited and divided into three groups based on DXA (normal, osteopenia, and osteoporosis). A total of 109 participants were included in this study and split into healthy (39/109, 35.8%), osteopenia (35/109, 32.1%), and osteoporosis groups (35/109, 32.1%). Serum concentrations of serotonin, fat-soluble vitamins, and bone turnover markers of participants were measured. Stepwise discriminant analysis was performed to identify efficient predictors for osteoporosis. The prediction model was developed based on Bayes and Fisher’s discriminant functions, and validated via leave-one-out cross-validation. Normal and empirical volume under the receiver operating characteristic (ROC) surface (VUS) tests were used to evaluate predictive effects of variables in the prediction model.Results: Significant variables including oestrogen (E2), total procollagen type 1 amino-terminal propeptide (TP1NP), parathyroid hormone (PTH), BMI, vitamin K, serotonin, osteocalcin (OSTEOC), vitamin A, and vitamin D3 were used for the development of the prediction model. The training accuracy for normal, osteopenia, and osteoporosis is 74.4% (29/39), 80.0% (28/35), and 85.7% (30/35), respectively, while the total training accuracy is 79.8% (87/109). The internal validation showed excellent performance with 72.5% testing accuracy (72/109). Among these variables, serotonin and vitamin K exert important roles in the prediction of osteoporosis.Conclusion: We successfully developed and validated a novel prediction model for osteoporosis based on serum concentrations of serotonin, fat-soluble vitamins, and bone turnover markers. In addition, interactive communication between serotonin and fat-soluble vitamins was observed to be critical for bone health in this study.Cite this article: Bone Joint Res 2025;14(2):111–123.